breaking

J&J Restructures Pharma Supply Chain, Eyes $750M in Exit Costs

Johnson & Johnson is undertaking a significant restructuring of its pharmaceutical supply chain, centered on its innovative medicine division. The company plans to divest from certain manufacturing and distribution facilities. Total restructuring costs are expected to reach up to $750 million, the company disclosed. The pharmaceutical giant did not specify timelines for facility closures or alternative sourcing arrangements.